- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 17,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- nebivolol, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 75
- States / cities
- Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Interventions
- SPY001, SPY002, SPY003, Placebo
- Drug · Other
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Canoga Park, California • La Jolla, California • Lancaster, California + 24 more
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- NS-018
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more
- Conditions
- Dyslipidemia
- Interventions
- LCP-AtorFen, atorvastatin, fenofibrate
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 7,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
- Conditions
- Alopecia Areata
- Interventions
- Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Standard of Care
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 27 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 18 more
- Conditions
- Cerebral Aneurysm, Menopause, Treatment
- Interventions
- Estradiol, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 40 Years to 52 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Peripheral Arterial Disease
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Chicago, Illinois
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
- Drug · Other
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
- Conditions
- Cancer Risk, Breast Cancer Risk
- Interventions
- Magnetic resonance imaging (MRI), Artificial Intelligence (AI)
- Procedure · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 40 Years to 89 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
- Conditions
- Prostate Cancer (Diagnosis)
- Interventions
- The Stockholm3 test
- Diagnostic Test
- Lead sponsor
- Karolinska Institutet
- Other
- Eligibility
- 45 Years to 75 Years · Male only
- Enrollment
- 2,152 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
- Interventions
- docetaxel, cisplatin, hydroxyurea, fluorouracil, chemotherapy, radiotherapy
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 14 more
- Conditions
- Mesothelioma
- Interventions
- ADI-PEG 20 plus Pem Platinum, Placebo plus Pem Platinum
- Drug · Other
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Occupational Stress
- Interventions
- Not listed
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
- Interventions
- Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
- Other · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 552
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
- Conditions
- Colorectal Cancer
- Interventions
- irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 430
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
- Conditions
- Overactive Bladder
- Interventions
- Solifenacin
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Dysphagia, Achalasia, Esophageal, Ineffective Esophageal Motility
- Interventions
- FLIP, HRM, Prucalopride
- Diagnostic Test · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure
- Interventions
- Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
- Drug · Device
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
- Interventions
- ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo
- Drug
- Lead sponsor
- Allena Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more